Lung Cancer in Non-smokers

Dear Colleagues,

Lung cancer in never smokers is a significant health concern worldwide and is among the most common causes of cancer-related mortality. There has been increasing concern that the incidence of never-smoking-related lung cancer may be rising. In the past two decades, an increasing volume of research has focused on this specific and distinct variant of lung cancer and has increased our understanding of the epidemiology, genetics, natural history, radiologic characteristics, response to treatment, and outcomes associated with lung cancer in never smokers (LCINS). Unfortunately, significant gaps in knowledge continue to exist and the ability to undertake large-scale population-based studies is hampered by the lack of coordinated databases and biorepositories with adequate and reliable information on smoking status.

In order to better understand this complex disease, we are pleased to invite you to contribute comprehensive and up-to-date review articles that provide the most authoritative compendium of knowledge on LCINS to date. The aim of this Special Issue is to summarize the highest quality research to date, identify ongoing knowledge gaps and propose LCINS-related clinical and research initiatives. This Special Issue aims to focus on the following ten LCINS areas of critical importance:

1. Clinical epidemiology and risk factors;
2. Genetics, biology, and molecular carcinogenesis;
3. Pathologic characteristics and subtypes;
4. Screening for lung cancer in never smokers, focused on efficacy, outcomes, overdiagnosis and overtreatment;
5. Radiologic characteristics and natural history;
6. Targeted therapy, systemic therapy, immunotherapy, and novel therapeutics, and clinical outcomes;
7. Statistics, databases, and data analysis for LCINS;
8. Biomarkers for diagnosis, prognosis, and monitoring;
9. Surgical outcomes for LCINS;
10. Healthcare disparities in LCINS.

Any additional research ideas or concepts are welcome. We look forward to receiving your contributions.

Sincerely,

Dr. Andrew J. Kaufman
Prof. Dr. Raja M. Flores
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• lung cancer in never smokers
• adenocarcinoma
• clinical epidemiology
• risk factors
• diagnosis
• treatment
• biomarkers